Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation-Reference-Cited by-同舟云学术

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation

Published:2018 Issue:2 Volume:22 Page:113-117
ISSN:1428-2526
Container-title:Współczesna Onkologia
language:
Short-container-title:wo

Author:

Frankiewicz Andrzej,Saduś-Wojciechowska Maria,Najda Jacek,Czerw Tomasz,Mendrek Włodzimierz,Sobczyk-Kruszelnicka Małgorzata,Soska Katarzyna,Ociepa Małgorzata,Hołowiecki Jerzy,Giebel Sebastian

Publisher

Termedia Sp. z.o.o.

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation;BMC Cancer;2024-08-13

2. BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial;eClinicalMedicine;2023-12

3. Conditioning regimens: balancing efficacy and toxicity;Leukemia & Lymphoma;2023-06-07

4. Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation;Leukemia & Lymphoma;2023-05-08

5. BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy;Scientific Reports;2021-07-07